no longer losing weight on tirzepatide GLP-1 Weightloss New weight loss program: Tirzepatide.

without talking to a doctor or sharing medical records

The AlfaBodY platform enables faster development of more efficacious biologic drugs

Mounjaro has received FDA Fast Track designation to speed up its path for FDA submission for treating adults with obesity, or overweight with weight-related health conditions.In the SURMOUNT-1 clinical trial the average weight loss after 72 weeks was 15% for the 5mg dose, 19.5% for the 10mg dose and 20.9% for the 15mg dose.Mounjaro isnotFDA approved as a weight loss medication.Important information:Mounjaro may cause thyroid C-cell tumors

Numerators GLP-1 solutions combine deep, longitudinal insights with full-channel purchase behavior to help you navigate the evolving impacts of GLP-1 drugs on your consumers and the market.

Download itHERE Have an idea for a future episode?Share it with us [email protected]

The short answer is there is no difference